PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ASSURE study of experimental agent to raise HDL yields 'disappointing and surprising' results

Hot Line III late-breaking trials

2013-09-02
(Press-News.org) AMSTERDAM, The Netherlands, 2 September2013 – The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study.

The lack of efficacy of RVX-208 is "disappointing and surprising, given promising earlier findings," noted lead investigator Stephen Nicholls MBBS, PhD, Deputy Director at the South Australian Health and Medical Research Institute, Professor of Cardiology at the University of Adelaide and Consultant Cardiologist at the Royal Adelaide Hospital in Adelaide, Australia.

However, the failure of RVX-208 to incrementally impact atherosclerotic plaque should not be interpreted as a failure of the hypothesis that increasing the level and activity of HDL could result in this benefit, he said.

"RVX-208 represents the first epigenetic foray into the metabolic treatment of cardiovascular disease, and ongoing clinical trials will evaluate the potential cardiovascular efficacy of other agents that target HDL."

ASSURE was a prospective, randomized, double-blind clinical trial carried out at 60 centers.

It randomized 323 patients with low HDL and coronary disease who had a target blood vessel for imaging with less than 50% stenosis.

All patients received treatment with either atorvastatin 10-40 mg daily or rosuvastatin 5-20 mg daily during the study and were also randomized to receive either RVX-208 100 mg (n=244) or placebo (n=80) twice daily for 26 weeks.

The primary and secondary outcomes of the study were change from baseline in percent atheroma volume (PAV) and normalized total atheroma (TAV), both measures of the amount of plaque present in the coronary artery.

Intravascular ultrasonography was used at baseline and the end of the study to measure these outcomes.

Of the 281 patients that remained in the study and had this imaging, while a trend towards plaque regression was observed with RVX-208 compared with baseline, there was no significant difference in efficacy outcomes between the groups, said Dr. Nicholls.

However, there were more discontinuations due to adverse events in the RVX-280 group (3.7% vs. 2.5%) as well as significantly more elevations of liver enzymes at triple the normal limit or more (7.0% vs. 0%, P=0.009).

In terms of efficacy, PAV decreased by 0.40% in the RVX-208 group compared to 0.30% in the placebo group ( P=0.81) and TAV decreased by 4.2 mm3 vs 3.8 mm3 respectively (P=0.86).

HDL cholesterol increased by 10.9% in the RVX-280 group compared to 7.7% in the placebo group (P=0.32), and LDL cholesterol decreased by 16.0% vs 17.6% with placebo (P=0.72).

There were no significant differences in cardiovascular events between the groups (13.8% in the RVX-2008 group vs 7.4% in the placebo; P=0.09), and all liver enzyme elevations occurred within the first 2 months of treatment with spontaneous resolution when the study drug was discontinued.

Additionally, the impact of RVX-208 on apoA1 levels from baseline was not significantly different from placebo (P=0.18). The levels increased by 10.6% (P END



ELSE PRESS RELEASES FROM THIS DATE:

Common blood pressure drug reduces aortic enlargement in Marfan syndrome

2013-09-02
AMSTERDAM, The Netherlands - A common drug that is used to treat high blood pressure in the general population has been found to significantly reduce a dangerous and frequently fatal cardiac problem in patients with Marfan syndrome. Results of the COMPARE (COzaar in Marfan PAtients Reduces aortic Enlargement) study reveal that patients treated with losartan (Cozaar) had a significantly reduced rate of aortic enlargement after 3 years compared to patients who did not receive the treatment. "Our study is the first large, prospective randomized study to assess the effects ...

Treatment with the anti-diabetic drug alogliptin does not increase CV risk in patients with ACS

2013-09-02
AMSTERDAM, The Netherlands – Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial presented at the European Society of Cardiology Congress. "Compared with placebo, treatment with alogliptin resulted in similar rates of the primary endpoint, which was a composite of cardiovascular death, myocardial ...

Move it and lose it: Every 'brisk' minute counts

2013-09-01
To win the war against weight gain, it turns out that every skirmish matters – as long as the physical activity puts your heart and lungs to work. In a new study published today in the American Journal of Health Promotion, University of Utah researchers found that even brief episodes of physical activity that exceed a certain level of intensity can have as positive an effect on weight as does the current recommendation of 10 or more minutes at a time. "What we learned is that for preventing weight gain, the intensity of the activity matters more than duration," says ...

Anticoagulant does not reduce rate of ischemic events among certain patients undergoing PCI

2013-09-01
Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non–ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013 "Major progress has been made in ...

Big belly increases death risk in heart attack survivors

2013-09-01
Amsterdam, The Netherlands – Sunday 1 September 2013 : Having a big belly increases the risk of death in heart attack survivors, according to research presented at ESC Congress 2013 by Professor Tabassome Simon and Professor Nicolas Danchin from France. The findings from the FAST-MI 2005 registry suggest that lifestyle interventions in heart attack patients should focus on losing abdominal fat. Professor Simon said: "The impact of obesity on long term mortality and cardiovascular complications in the general population has been the object of recent debate. Much emphasis ...

Listening to favorite music improves endothelial function in CAD

2013-09-01
Professor Deljanin Ilic said: "In the setting of cardiovascular risk factors and cardiovascular disease the endothelium loses its normal function.1 Since endothelium derived nitric oxide is necessary to maintain an adequate vascular response, correction of endothelial dysfunction has become a goal of therapy." She added: "Exercise training has been shown to improve endothelial function and is the cornerstone of a multifaceted programme of cardiovascular rehabilitation. However, little is known about the role of music in cardiovascular rehabilitation or the effects of ...

Physical activity decreases sudden cardiac death risk in unfit men

2013-09-01
Dr Laukkanen said: "Sudden cardiac death (SCD) accounts for approximately 50% of deaths from coronary heart disease. SCD typically occurs shortly after the onset of symptoms, leaving little time for effective medical interventions, and most cases occur outside hospital with few or no early warning signs. Finding ways to identify individuals at elevated risk of SCD would allow early interventions on risk factors to be implemented." The current study investigated the impact of high leisure-time physical activity (LTPA) combined with cardiorespiratory fitness (CRF) on risk ...

Cold weather produces more heart attacks

2013-09-01
Professor Claeys said: "Air pollution and temperature changes are the most frequently reported environmental triggers for acute myocardial infarction (AMI). Epidemiologic studies have focused mainly on one environmental condition, but most environmental triggers are related to each other and may attenuate or reinforce the triggering effect of a single environmental factor." He added: "Better knowledge of the impact of environment on AMI will help medical care providers and policy makers to optimise prevention strategies for a target risk population." The present study ...

Cardiovascular risk factors highest in winter and lowest in summer

2013-09-01
Dr Marques-Vidal said: "Deaths from cardiovascular disease are higher in winter and lower in summer. We decided to conduct a large scale study to see whether cardiovascular risk factors have a seasonal pattern which could explain the seasonality in deaths." The study used cross-sectional data from 10 population based studies in 7 countries. Information was obtained on cardiovascular risk factors in 107,090 subjects aged 35 to 80 years. The country breakdown was as follows: 21,128 subjects in Belgium, 15,664 in Denmark, 1,626 in France, 18,370 in Italy, 25,532 in Norway, ...

Out-of-hospital cardiac arrest survival just 7 percent

2013-09-01
Amsterdam, The Netherlands – Sunday 1 September 2013: Survival for out-of-hospital cardiac arrest is just 7%, according to research presented at ESC Congress 2013 by Professor Xavier Jouven and Dr Wulfran Bougouin from France. Professor Jouven said: "Sudden cardiac death (SCD) is an important public health problem, accounting for more than 400,000 deaths every year. The main cause is ventricular tachyarrhythmias which are often triggered by acute ischaemic events that can occur in persons with or without known heart disease. The survival rate from cardiac arrest has remained ...

LAST 30 PRESS RELEASES:

Pink skies

Monkeys are world’s best yodellers - new research

Key differences between visual- and memory-led Alzheimer’s discovered

% weight loss targets in obesity management – is this the wrong objective?

An app can change how you see yourself at work

NYC speed cameras take six months to change driver behavior, effects vary by neighborhood, new study reveals

New research shows that propaganda is on the rise in China

Even the richest Americans face shorter lifespans than their European counterparts, study finds

Novel genes linked to rare childhood diarrhea

New computer model reveals how Bronze Age Scandinavians could have crossed the sea

Novel point-of-care technology delivers accurate HIV results in minutes

Researchers reveal key brain differences to explain why Ritalin helps improve focus in some more than others

Study finds nearly five-fold increase in hospitalizations for common cause of stroke

Study reveals how alcohol abuse damages cognition

Medicinal cannabis is linked to long-term benefits in health-related quality of life

Microplastics detected in cat placentas and fetuses during early pregnancy

Ancient amphibians as big as alligators died in mass mortality event in Triassic Wyoming

Scientists uncover the first clear evidence of air sacs in the fossilized bones of alvarezsaurian dinosaurs: the "hollow bones" which help modern day birds to fly

Alcohol makes male flies sexy

TB patients globally often incur "catastrophic costs" of up to $11,329 USD, despite many countries offering free treatment, with predominant drivers of cost being hospitalization and loss of income

Study links teen girls’ screen time to sleep disruptions and depression

Scientists unveil starfish-inspired wearable tech for heart monitoring

Footprints reveal prehistoric Scottish lagoons were stomping grounds for giant Jurassic dinosaurs

AI effectively predicts dementia risk in American Indian/Alaska Native elders

First guideline on newborn screening for cystic fibrosis calls for changes in practice to improve outcomes

Existing international law can help secure peace and security in outer space, study shows

Pinning down the process of West Nile virus transmission

UTA-backed research tackles health challenges across ages

In pancreatic cancer, a race against time

Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers

[Press-News.org] ASSURE study of experimental agent to raise HDL yields 'disappointing and surprising' results
Hot Line III late-breaking trials